Stockscreener 앱 받기
13.12
0.68%
-0.14
전일 마감가:
$13.26
열려 있는:
$13.13
하루 거래량:
27,052
Relative Volume:
0.14
시가총액:
$193.86M
수익:
$6.39M
순이익/손실:
$-117.26M
주가수익비율:
-1.0512
EPS:
-12.4807
순현금흐름:
$-79.08M
1주 성능:
-0.08%
1개월 성능:
+25.43%
6개월 성능:
+8.57%
1년 성능:
-44.36%
1일 변동 폭
$12.80
$13.55
1주일 범위
$12.66
$13.98
52주 변동 폭
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
명칭
Korro Bio Inc
전화
617-468-1999
주소
60 FIRST STREET, CAMBRIDGE
Compare KRRO vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
13.16 | 190.84M | 6.39M | -117.26M | -79.08M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
542.68 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
790.37 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,028.30 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.03 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
206.55 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2026-02-17 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2026-01-29 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2026-01-29 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2026-01-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2026-01-28 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2026-01-28 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-11-13 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-11-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2025-11-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-11-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-11-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-13 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2025-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-16 | 개시 | Chardan Capital Markets | Buy |
| 2025-01-10 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Raymond James | Strong Buy |
| 2024-08-14 | 개시 | William Blair | Outperform |
| 2024-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2024-02-27 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-04 | 개시 | H.C. Wainwright | Buy |
| 2023-11-29 | 개시 | RBC Capital Mkts | Outperform |
| 2023-11-10 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2023-02-13 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-01-27 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-22 | 개시 | B. Riley Securities | Buy |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-10-28 | 개시 | Cowen | Outperform |
| 2019-10-28 | 개시 | Goldman | Buy |
| 2019-10-28 | 개시 | JP Morgan | Overweight |
모두보기
Korro Bio Inc 주식(KRRO)의 최신 뉴스
Korro Bio (NASDAQ:KRRO) Director Sells $398,552.00 in Stock - MarketBeat
Korro Bio (KRRO) director-tied funds sell 28K shares on Aug. 19 - Stock Titan
Balyasny Asset Management L.P. Reduces Stake in Korro Bio Inc (K - GuruFocus
Korro Bio Moves KRRO-121 Into First Human Trials, Raising the Stakes in Rare Disease RNA Editing - TipRanks
Korro Bio (NASDAQ:KRRO) Receives "Buy" Rating from HC Wainwright - MarketBeat
Form 8K Korro Bio Inc For: 19 August By Investing.com - Investing.com Nigeria
Korro Bio Advances KRRO-121 Into First Human Trial - TipRanks
Korro Bio, Inc. Announces Submission To Australian Alfred Health Human Ethics Committee To Initiate First-In-Human Phase 1/2 Clinical Trial For KRRO-121 - marketscreener.com
Korro (KRRO) Quarter in Focus: The Bottom-Line Figure Outpaces Its Comparison in the Latest Reading - vinanet.vn
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
KRRO Q2 2026 Earnings: Wider-Than-Expected Loss Avoided as Cost Discipline Drives 27.65% EPS BeatEarnings Yield Analysis - vinanet.vn
Insider Selling: Korro Bio (NASDAQ:KRRO) Director Sells $29,916.28 in Stock - MarketBeat
Korro Bio director Jean Francois Formela sells $29,916 in shares By Investing.com - Investing.com Australia
Korro Bio director Jean Francois Formela sells $29,916 in shares - Investing.com
Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan - Stock Titan
Korro Bio (NASDAQ:KRRO) Major Shareholder Acquires $19,283.78 in Stock - MarketBeat
Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock - Investing.com
Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock By Investing.com - Investing.com Canada
Korro Bio (KRRO) holder Lynx1 Capital reports 6,684-share indirect stock purchase - Stock Titan
Lynx1 Capital Management Lp Buys 5,222 Shares of Korro Bio (NASDAQ:KRRO) Stock - MarketBeat
HC Wainwright Has Strong Estimate for Korro Bio Q3 Earnings - marketbeat.com
All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy - Yahoo Finance
A US$42m Market Cap Boost Pleasing ToKorro Bio Insiders - webull.com
Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP) and Korro Bio (KRRO) - theglobeandmail.com
Korro Bio (NASDAQ:KRRO) Releases Quarterly Earnings Results, Beats Expectations By $0.22 EPS - marketbeat.com
Korro Bio (NASDAQ:KRRO) Upgraded at Wall Street Zen - MarketBeat
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Cantor Fitzgerald Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Korro Bio, Inc. expected to post a loss of $1.43 a shareEarnings Preview - TradingView
William Blair Maintains Korro Bio(KRRO.US) With Buy Rating - Moomoo
Raymond James reiterates Korro Bio stock rating on hyperammonemia outlook - Investing.com UK
Korro Bio Refines Capital Structure with Exchange Agreement - The Globe and Mail
Chardan Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Korro Bio earnings beat by $0.24, revenue topped estimates - Investing.com Canada
Korro Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Korro Bio Reports $18.9 Million Q2 Net Loss - Quiver Quantitative
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Korro Bio Swaps 1.0M Shares for Pre-Funded Warrants to Venrock at $0.001 Exercise Price - TradingView
Korro Bio, Inc. Q2 2026: Revenue $0M, Net loss $(18.9)M, EPS $(1.07) — 10-Q Summary - TradingView
Korro Bio CEO Highlights Strategic Payoff, Advancing New Therapies - Intellectia AI
Korro Bio (KRRO) CEO sells 5,802 shares of stock to cover taxes - Stock Titan
Korro Bio Inc. (KRRO) Gains 1.23%: Trading Between $10.92 Support and $12.06 ResistanceMerger Arbitrage - vinanet.vn
Korro Bio (KRRO) Expected to Post Earnings on Tuesday - MarketBeat
Korro Bio (KRRO) Climbs 5.68% to $11.35 as RNA Editing Play Draws Fresh Buyer InterestFund Manager Survey - dars.gov.et
KRRO Q1 2026 Earnings: Narrower-than-Expected Loss Beats Estimates as Shares Slip 0.77%Post-Earnings Drift - vinanet.vn
KRRO Q1 2026 Earnings: Narrower-than-Expected Loss Signals Disciplined SpendingManagement Guidance Update - vinanet.vn
ADAR1 Capital Management LLC Takes Position in Korro Bio, Inc. $KRRO - MarketBeat
Korro Bio Inc (KRRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
KRRO|Korro Bio Inc|Price:10.370|Chg%:-0.080 - TradingKey
Korro Bio Inc (KRRO) Institutional Confidence - TradingKey
Korro Bio Inc (KRRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Korro Bio Inc (KRRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
7.55%
자본화:
|
볼륨(24시간):